Cognitive and behavioral dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioral impairment (MBI), and into a clinically manifest stage recognized by...
M. Benatar, E. Huey, Chiadikaobi Onyike et al.· Brain : a journal of neurolo...· 1 citation
An international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for the detection of either ALS or FTD pathobiology prior to phenoconversion and/or predict phenoconversion in at risk individuals.
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
DNA methylation (DNAm)-based tools are predominantly developed in European ancestry, high-income populations, raising questions on their applicability in diverse and rural settings, and it is found no significant contribution to genome-wide DNAm or predictive sites used in these tools are found.
Beryl C. Zhuang, Chaini Konwar, Iliana V. Kohler et al.· iScience· 0 citations
Greater TDP-43 burden was most closely associated with antemortem clinical decline rather than cumulative aggregation through the disease course, suggesting that the temporal dynamics of protein aggregation may differ among FTLD proteinopathies, with implications for the interpretation of FTLD-Tau and FTLD-TDP‑specific...
R. Magee, Sharon X. Xie, DT Ohm et al.· Neurology· 1 citation
A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
M. Benatar, SJ Barmada, Gregory A. Jicha et al.· JAMA Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
